Spotlight: LakePharma buys Blue Sky BioServices

Belmont, CA-based LakePharma, which covers the biologics CRO space, has snapped up Massachusetts antibody CRO specialist Blue Sky BioServices for an undisclosed fee. The combined company will be known as LakePharma and according to a statement from the firm becomes the largest dedicated biologics CRO in the U.S. It will provide a broad range of protein and antibody-related development services to the pharma and biotech markets. Release

> The German drug discovery/CRO firm Evotec has spun off one of its drug units to create "Topas Therapeutics GmbH"--a new biotech that will be funded by both Evotec and VCs. The firm's lead MS candidate is set for its first clinical trial next year, with the spinoff being run by former Evotec CEO Dr. Timm Jessen. News

> NAMSA, the medical research organization, has partnered with Veeva Systems to replace its paper-based system for managing clinical trial documents using the Veeva Vault eTMF system. Release

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Suggested Articles

Major CRO player Pharmaceutical Product Development is set to go back on the public markets after announcing its IPO plans.

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.